AstraZeneca (AZN) Stock Forecast & Price Target

AstraZeneca
Bull Case

Here are some ways that investors could benefit from investing in AstraZeneca PLC:

• The company recently completed a $2 billion strategic equity investment in Summit Therapeutics, a move that significantly deepens its oncology pipeline and positions it to leverage advanced cancer treatments, which is a major catalyst for long-term growth.
• AstraZeneca PLC is currently trading at $12,300.00, which is well below the consensus price target of £150.00 set by sell-side brokerages, suggesting substantial potential upside for investors as the stock recovers from recent lows.
• The stock has a very low beta of 0.21, indicating that it is significantly less volatile than the broader market, which makes it an attractive defensive holding for investors seeking stability during periods of economic uncertainty.
• Recent positive clinical data for tozorakimab in the treatment of COPD (Chronic Obstructive Pulmonary Disease) demonstrates the company's continued innovation in its Respiratory & Immunology therapy area, reinforcing its leadership in high-growth medical segments.
• The company is committing over $1 billion to a new R&D center in Massachusetts, signaling a strong commitment to expanding its research capabilities and workforce, which supports its long-term strategy of developing next-generation prescription medicines.